Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma.
Hajime YonezawaYoshitaka NaritaMotoo NaganeKazuhiko MishimaYasuhito TeruiYoshiki ArakawaKatsunori AsaiNoriko FukuharaKazuhiko SugiyamaNaoki ShinojimaArata AoiRyo NishikawaPublished in: Neuro-oncology advances (2024)
The results demonstrated the long-term clinical benefit of tirabrutinib, with deep and durable response in a subset of patients and acceptable safety profile, while KPS and QoL scores were maintained.
Keyphrases
- end stage renal disease
- diffuse large b cell lymphoma
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute myeloid leukemia
- acute lymphoblastic leukemia
- peritoneal dialysis
- prognostic factors
- multiple myeloma
- randomized controlled trial
- clinical trial
- patient reported outcomes
- hodgkin lymphoma
- double blind